Editorial Comment
- PMID: 39996507
- PMCID: PMC12064354
- DOI: 10.1097/JU.0000000000004482
Editorial Comment
Comment on
-
Gemcitabine vs Bacillus Calmette-Guérin for Intravesical Therapy in Treatment-Naïve Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer.J Urol. 2025 Jun;213(6):730-738. doi: 10.1097/JU.0000000000004472. Epub 2025 Feb 10. J Urol. 2025. PMID: 39929084
References
-
- Khene Z, Bhanvadia R, Attia S, et al. Gemcitabine versus Bacillus Calmette-Guerin for Intravesical Therapy in Treatment Naïve Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer. J Urol. 2025 - PubMed
-
- Lotan Y, Krishna V, Abuzeid WM, et al. Predicting Response to Intravesical Bacillus Calmette-Guérin in High-Risk Nonmuscle-Invasive Bladder Cancer Using an Artificial Intelligence-Powered Pathology Assay: Development and Validation in an International 12-Center Cohort. J Urol. 2025 - PubMed
-
- Tan WS, McElree IM, Davaro F, et al. Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2023 - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
